Aurobindo Pharma USFDA nod adds 579th ANDA portfolio

What the USFDA approval is for

Aurobindo Pharma said it has received final approval from the US Food and Drug Administration (USFDA) to manufacture and market Glycerol Phenylbutyrate Oral Liquid, 1.1 grams per mL. The product is a generic version that the company described as bioequivalent and therapeutically equivalent to the reference-listed drug Ravicti. Ravicti is marketed by Horizon Therapeutics U.S. Holding LLC. The approval adds another product to Aurobindo’s US pipeline, where filings and approvals are tracked through the ANDA process.

Manufacturing site and launch plan

The company said the product will be manufactured at its Unit-III facility. It also said the launch will happen immediately. For investors, the combination of a final approval and an “immediate launch” statement generally signals that the company has planned supply readiness and commercial preparations. But the actual pace of market capture typically depends on channel stocking and competitive intensity in the molecule.

Market size of the molecule in the US

Aurobindo cited IQVIA MAT data to estimate the market size of Glycerol Phenylbutyrate Oral Liquid at USD 50.2 million for the 12 months ending February 2026. This figure provides a reference point for the addressable branded and generic opportunity in the US. The estimate is specific to the period stated and does not by itself indicate Aurobindo’s expected revenue share.

What the medicine is used for

Glycerol phenylbutyrate oral liquid is indicated as a nitrogen-binding agent for the chronic management of patients with urea cycle disorders (UCDs). The company noted it is used in patients who cannot be adequately managed through dietary protein restriction and amino acid supplementation alone. UCDs are typically treated through long-term management, and therapies in this category are designed to help control nitrogen levels.

ANDA approval count: where Aurobindo stands

With this approval, Aurobindo Pharma said its total ANDA approvals from the USFDA stand at 579. This includes 556 final approvals and 23 tentative approvals, as stated in the company’s update. The ANDA count is a key operating metric for Indian pharma companies with a large US generics presence because it reflects both historical execution and the steady flow of approvals.

Stock move and immediate market reaction

On the day of the update, Aurobindo Pharma shares rose 0.09% to Rs 1,387.30 on the BSE, according to the provided market data. The price move was marginal, suggesting the approval was absorbed as part of the company’s steady cadence of US regulatory outcomes. Separately provided trading data also showed the stock around Rs 1,387.90 with a 5-day change of +2.82% and a 1st Jan change of +17.28%.

Financial snapshot: Q3 FY26 performance

Aurobindo Pharma reported a 7.6% rise in consolidated net profit to Rs 9,102.9 million in Q3 FY26, alongside a 9% increase in net sales to Rs 86,045.1 million versus Q3 FY25. These figures provide context on the company’s scale and profitability as it continues to expand its portfolio in the US. While approvals can support growth, quarterly performance is also influenced by product mix, pricing, and base business momentum.

Recent USFDA activity in April 2026 (context)

Separately, another update dated April 7, 2026 said Aurobindo Pharma received USFDA final approval for Dapagliflozin Tablets, 5 mg and 10 mg, therapeutically equivalent to Farxiga of AstraZeneca AB. That update cited an estimated market size of USD 10,200 million for the 12 months ending February 2026 (IQVIA MAT). It also referenced total ANDA approvals of 579 as of March 31, 2026, with a split of 554 final approvals and 25 tentative approvals. The headline takeaway from these disclosures is that Aurobindo has continued to add products across therapy areas through USFDA clearances.

Key facts at a glance

Why the approval matters for investors

For Indian pharma companies, USFDA final approvals are a practical milestone because they convert a pipeline asset into a commercial product opportunity. In this case, the company has paired the approval with an immediate launch plan, which indicates intent to monetize without delay. The disclosed market size is modest compared with large chronic therapies, but it can still be meaningful when added to a wide base of products.

Conclusion

Aurobindo Pharma’s USFDA final approval for Glycerol Phenylbutyrate Oral Liquid adds another marketed product to its US generics portfolio, with manufacturing planned at Unit-III and an immediate launch. The company has pegged the US market size at USD 50.2 million for the year ended February 2026, while maintaining an overall USFDA ANDA approval count of 579. Investors will watch how the launch translates into quarterly sales alongside the company’s existing growth and profitability trends.